Effective treatment of non-fusion RET intragenic deletion lung adenocarcinoma with pralsetinib: a case report [PDF]
Frontiers in MedicineRET fusions, the most common oncogenic RET alterations, occur in approximately 1–2% of non-small cell lung cancer (NSCLC) cases and represent well-established therapeutic targets.
Wenjun Li +6 more
doaj +6 more sources
A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review [PDF]
Frontiers in MedicineSelective rearranged during transfection (RET) tyrosine kinase inhibitor, pralsetinib, demonstrated clinical efficacy and was well tolerated in lung and thyroid cancers with RET gene mutations or fusions in clinical trials.
François Poumeaud +11 more
doaj +6 more sources
Pathologic complete response to pralsetinib in stage IV RET-positive non-small cell lung cancer: A case report [PDF]
Respiratory Medicine Case ReportsNeoadjuvant therapy with tyrosine kinase inhibitors has been proposed as a feasible approach for downstaging potential resectable non-small cell lung cancer (NSCLC).
Xinxin Chen +7 more
doaj +3 more sources
Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system [PDF]
Frontiers in PharmacologyAimsThe objective of this study is to compare the adverse events (AEs) associated with pralsetinib and selpercatinib.MethodsTo evaluate the imbalance of AEs linked to pralsetinib and selpercatinib in real-world data, the reporting odds ratio (ROR) was ...
Qiong Jie +4 more
doaj +4 more sources
Real-world FAERS safety analysis of Pralsetinib [PDF]
Scientific ReportsThe FDA has approved pralsetinib as a chemotherapeutic drug for the treatment of individuals with cancers such as medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), and non-small cell lung cancer (NSCLC).
Dongdong Zhang +6 more
doaj +4 more sources
A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib [PDF]
Frontiers in OncologyBackgroundPralsetinib, a selective oral inhibitor of rearranged during transfection (RET) fusion proteins and oncogenic RET mutants, has shown significant efficacy in treating RET fusion-positive non-small cell lung cancer and thyroid cancer.
Yi Yin, Fengli Sun, Youpeng Jin
doaj +4 more sources
Pralsetinib treatment for multiple fusions in lung adenocarcinoma: a case report
Journal of International Medical Research, 2022 Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection ( RET ) fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been used
Xiangming Cao +6 more
doaj +4 more sources
Understanding CYP3A4 and P‐gp mediated drug–drug interactions through PBPK modeling – Case example of pralsetinib [PDF]
CPT: Pharmacometrics & Systems PharmacologyPralsetinib, a potent and selective inhibitor of oncogenic RET fusion and RET mutant proteins, is a substrate of the drug metabolizing enzyme CYP3A4 and a substrate of the efflux transporter P‐gp based on in vitro data.
Christine Bowman +7 more
doaj +4 more sources
Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib [PDF]
Frontiers in GeneticsAnaplastic lymphoma kinase (ALK) fusion, an oncogenic driver alteration, accounts for 5%–6% of non-small cell lung cancer (NSCLC) patients. ALK tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in advanced ALK-rearranged NSCLC ...
Feng Jin +4 more
doaj +4 more sources
Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer [PDF]
Frontiers in MedicineBackgroundPralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs).
Lei Wang +9 more
doaj +4 more sources